Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.

Journal: Journal of clinical medicine research
Published Date: Dec 31, 2016

Abstract

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are novel agents used to treat type 2 diabetic patients. We investigated the efficacy of the SGLT2 inhibitor ipragliflozin on diabetic nephropathy in Japanese patients with type 2 diabetes.

Authors

  • Daisuke Ito
    Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan; Department of Internal Medicine, Ogawa Red Cross Hospital, Saitama, Japan.
  • Emi Ikuma-Suwa
    Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.
  • Kazuyuki Inoue
    Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan; Department of Internal Medicine, Ogawa Red Cross Hospital, Saitama, Japan.
  • Kimie Kaneko
    Department of Nursing, Ogawa Red Cross Hospital, Saitama, Japan.
  • Morifumi Yanagisawa
    Department of Internal Medicine, Ogawa Red Cross Hospital, Saitama, Japan; Satsuki Medical Clinic, Saitama, Japan.
  • Kouichi Inukai
    Department of Diabetes and Endocrinology, Higashiyamato Hospital, Tokyo, Japan.
  • Mitsuhiko Noda
    Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.
  • Akira Shimada
    Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals